NSE: LALPATHLAB | BSE: 539524

Mid-range Performer

Download real time

3003.20 -40.80 (-1.34%)

30.94% Gain from 52W Low

86,880 NSE+BSE Volume

NSE 03 Dec, 2025 1:32 PM (IST)

25,159.5

Market Cap

Market Runner Up

Beta 1Year

Very Low volatility

Dr. Lal Pathlabs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LALPATHLAB, BSE:539524 Dr. Lal Pathlabs Ltd.

Dr. Lal Pathlabs Ltd.

19 Jun 2024

3003.20

-1.34%

Corner Office view: Spotlight on bundling and Suburban ramp up

Buy: Dr. Lal Pathlabs Ltd.

Emkay

We met DLPL’s MD Dr. Om Manchanda to gauge competitive intensity and its strategy to boost volumes. Meeting KTAs are: 1) DLPL is increasingly witnessing the ‘bundling’ phenomenon as doctors are recommending multiple tests to ascertain accurate prognosis.

Dr. Lal Pathlabs Ltd. is trading below its 30 day SMA of 3118.0

Dr. Lal Pathlabs Ltd.

10 May 2024

3003.20

-1.34%

Swasthfit drives the beat

Buy: Dr. Lal Pathlabs Ltd.

Emkay

DLPL posted a robust quarter, with revenue growing 11% YoY on the back of
sample volume increasing 9% YoY and Swasthfit contributing 24% to the
topline.

Dr. Lal Pathlabs Ltd. has an average target of 3111.40 from 5 brokers.

Dr. Lal Pathlabs Ltd.

08 Aug 2023

3003.20

-1.34%

DR. LAL PATHLABS LIMITED

Sell: Dr. Lal Pathlabs Ltd.

Recommendation Target

Geojit BNP Paribas

Dr. Lal Pathlabs Ltd. has an average target of 3111.40 from 5 brokers.

Dr. Lal Pathlabs Ltd.

29 Jul 2023

3003.20

-1.34%

Seasonality shrinks volumes though boost margins

Accumulate: Dr. Lal Pathlabs Ltd.

Target

ICICI Securities Limited

Dr Lal’s Pathlabs’ Q1 volume growth at 2.5% was impacted to some extent due to seasonality. Favourable test mix and traction in Swasthfit improved realisation per patient by 8.5% to INR 789 and aided gross margin expansion of 181bps YoY.

Number of FII/FPI investors increased from 358 to 391 in Sep 2025 qtr.

Dr. Lal Pathlabs Ltd.

10 Feb 2023

3003.20

-1.34%

DR. LAL PATHLABS LIMITED

Hold: Dr. Lal Pathlabs Ltd.

Target

Geojit BNP Paribas

Dr. Lal Pathlabs Ltd. is trading below its 30 day SMA of 3118.0

Dr. Lal Pathlabs Ltd.

09 Nov 2022

3003.20

-1.34%

Margins improve despite slow growth

Accumulate: Dr. Lal Pathlabs Ltd.

ICICI Securities Limited

Dr Lal Pathlabs’ (Dr Lal) Q2FY23 performance was a mixed bag with slower-than-
expected growth in non-covid patient volumes, but healthy improvement in margins.

Dr. Lal Pathlabs Ltd. has an average target of 3111.40 from 5 brokers.

Dr. Lal Pathlabs Ltd.

10 Aug 2022

3003.20

-1.34%

DR. LAL PATHLABS LIMITED

Hold: Dr. Lal Pathlabs Ltd.

Target

Geojit BNP Paribas

Dr. Lal Pathlabs Ltd. is trading below its 30 day SMA of 3118.0

Dr. Lal Pathlabs Ltd.

16 Feb 2022

3003.20

-1.34%

DR. LAL PATHLABS LIMITED

Accumulate: Dr. Lal Pathlabs Ltd.

Target

Geojit BNP Paribas

Dr. Lal PathLabs Limited (DLPL) provides diagnostic and related healthcare tests and services in India and internationally. Company has 231 clinical laboratories, including National Reference Lab at Delhi and Regional...

Dr. Lal Pathlabs Ltd. is trading below its 30 day SMA of 3118.0

Dr. Lal Pathlabs Ltd.

05 Aug 2021

3003.20

-1.34%

DR. LAL PATHLABS LIMITED

Accumulate: Dr. Lal Pathlabs Ltd.

Target

Geojit BNP Paribas

With persistent focus of service parameters and timely turnarounds, DLPL was able to achieve robust growth in volume during the pandemic. Leveraging its dedicated network driven infrastructure and techenabled processes, we expect the company to be able to perform well in the expected third wave situation. Hence, we upgrade our rating on the...

Dr. Lal Pathlabs Ltd. has an average target of 3111.40 from 5 brokers.

Dr. Lal Pathlabs Ltd.

03 Aug 2021, 12:00AM

3003.20

-1.34%

Company Update - Valuation running way ahead of fundamentals - SELL

Sell: Dr. Lal Pathlabs Ltd.

Target

Prabhudas Lilladhar

unsustainable rise in volume of patients and samples (all time high) We reinitiate coverage on DLPL stock with Sell' rating, previously kept Under Review'. 1QFY22 earnings were higher than our estimates solely driven by additional volumes, due to large number of patients in the second wave. Business in core portfolio grew 15% YoY given 1) all collection centers and labs resumed operations much earlier than expected 2) high revenue...

Number of FII/FPI investors increased from 358 to 391 in Sep 2025 qtr.

Is Dr. Lal Pathlabs Ltd. worth buying?

230 Votes:

Buy 76.52%

Sell 14.35%

Hold 9.13%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf